这是一篇来自已证抗体库的有关
人类 PAK4的综述,是根据10篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合PAK4 抗体。
PAK4 同义词: serine/threonine-protein kinase PAK 4; p21 protein (Cdc42/Rac)-activated kinase 4; p21(CDKN1A)-activated kinase 4; protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs
艾博抗(上海)贸易有限公司
兔 单克隆(EPR2471(2)) | | 艾博抗(上海)贸易有限公司 PAK4抗体(Abcam, EPR2471(2))被用于被用于免疫印迹在小鼠样品上 (图 7e). Haematologica (2017) ncbi |
兔 多克隆 | | 艾博抗(上海)贸易有限公司 PAK4抗体(Abcam, ab62509)被用于被用于免疫印迹在人类样品上. Mol Cancer Ther (2015) ncbi |
赛默飞世尔
兔 多克隆 | | 赛默飞世尔 PAK4抗体(Thermo Scientific, PA5-17636)被用于被用于免疫印迹在人类样品上浓度为1:500 (图 4). Diagn Pathol (2015) ncbi |
兔 多克隆 | | 赛默飞世尔 PAK4抗体(Thermo Scientific, PA5-15120)被用于被用于免疫印迹在人类样品上浓度为1:500 (图 3). Diagn Pathol (2015) ncbi |
圣克鲁斯生物技术
小鼠 单克隆(B-6) | - 免疫组化-冰冻切片; 人类; 图 2
- 免疫印迹; 人类; 图 1
| 圣克鲁斯生物技术 PAK4抗体(Santa Cruz, sc-393367)被用于被用于免疫组化-冰冻切片在人类样品上 (图 2) 和 被用于免疫印迹在人类样品上 (图 1). PLoS ONE (2016) ncbi |
赛信通(上海)生物试剂有限公司
兔 多克隆 | | 赛信通(上海)生物试剂有限公司 PAK4抗体(Cell Signaling, 3242)被用于被用于其他在人类样品上 (图 4c). Cancer Cell (2018) ncbi |
兔 多克隆 | - 免疫沉淀; 小鼠; 图 1
- 免疫印迹; 小鼠; 1:1000; 图 1
| 赛信通(上海)生物试剂有限公司 PAK4抗体(Cell Signaling, 3242)被用于被用于免疫沉淀在小鼠样品上 (图 1) 和 被用于免疫印迹在小鼠样品上浓度为1:1000 (图 1). Nat Commun (2015) ncbi |
兔 多克隆 | | 赛信通(上海)生物试剂有限公司 PAK4抗体(Cell Signaling Technology, 3242)被用于被用于免疫印迹在人类样品上 (图 4). Oncotarget (2015) ncbi |
兔 多克隆 | | 赛信通(上海)生物试剂有限公司 PAK4抗体(Cell Signaling Technology, 3242)被用于被用于免疫印迹在人类样品上 (图 2). Cardiovasc Res (2015) ncbi |
兔 多克隆 | | 赛信通(上海)生物试剂有限公司 PAK4抗体(cell signalling, 3242)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 2a). Carcinogenesis (2014) ncbi |
西格玛奥德里奇
兔 多克隆 | | 西格玛奥德里奇 PAK4抗体(Sigma, SAB4504052)被用于被用于免疫印迹在人类样品上浓度为1:2000 (图 5a). J Neurochem (2015) ncbi |
Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y,
et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10
pubmed 出版商
Beauchemin H, Shooshtarizadeh P, Vadnais C, Vassen L, Pastore Y, Moroy T. Gfi1b controls integrin signaling-dependent cytoskeleton dynamics and organization in megakaryocytes. Haematologica. 2017;102:484-497
pubmed 出版商
Wang Y, Gratzke C, Tamalunas A, Wiemer N, Ciotkowska A, Rutz B,
et al. P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate. PLoS ONE. 2016;11:e0153312
pubmed 出版商
Shu X, Wu J, Sun H, Chi L, Wang J. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway. Diagn Pathol. 2015;10:177
pubmed 出版商
Civiero L, Cirnaru M, Beilina A, Rodella U, Russo I, Belluzzi E,
et al. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain. J Neurochem. 2015;135:1242-56
pubmed 出版商
Singh N, Kotla S, Dyukova E, Traylor J, Orr A, Chernoff J,
et al. Disruption of p21-activated kinase 1 gene diminishes atherosclerosis in apolipoprotein E-deficient mice. Nat Commun. 2015;6:7450
pubmed 出版商
Loganzo F, Tan X, Sung M, Jin G, Myers J, Melamud E,
et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14:952-63
pubmed 出版商
Chow H, Dong B, Duron S, Campbell D, Ong C, Hoeflich K,
et al. Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 2015;6:1981-94
pubmed
Komaravolu R, Adam C, Moonen J, Harmsen M, Goebeler M, Schmidt M. Erk5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1. Cardiovasc Res. 2015;105:86-95
pubmed 出版商
Kim T, Kang Y, Park Z, Kim Y, Hong S, Oh S,
et al. SH3RF2 functions as an oncogene by mediating PAK4 protein stability. Carcinogenesis. 2014;35:624-34
pubmed 出版商